Showing results (151-160 of 194) with videos related to
Sort By:
Pageof 20
The Lancet. Infectious Diseases|June 21, 2012
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trialStanislas Pol, Reem H Ghalib, Vinod K Rustgi, et al.The Lancet. Gastroenterology & Hepatology|April 8, 2019
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trialPhilippe Merle, Jean-Frederic Blanc, Jean-Marc Phelip, et al.Lancet (London, England)|December 10, 2016
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialJordi Bruix, Shukui Qin, Philippe Merle, et al.Liver International : Official Journal of the International Association for the Study of the Liver|October 15, 2013
Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trialsMichael P Manns, Jonathan McCone, Mitchell N Davis, et al.Journal of Hepatology|October 11, 2015
Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infectionStefan Zeuzem, Christophe Hézode, Jean-Pierre Bronowicki, et al.Journal of Hepatology|July 26, 2011
Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 studyJean-Pierre Zarski, Nathalie Sturm, Jérôme Guechot, et al.Lancet (London, England)|August 1, 2014
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort studyMichael Manns, Stanislas Pol, Ira M Jacobson, et al.JAMA|May 6, 2015
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infectionFred Poordad, William Sievert, Lindsay Mollison, et al.The Lancet. Oncology|December 13, 2021
Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association studyEric Trépo, Stefano Caruso, Jie Yang, et al.The Lancet. Infectious Diseases|March 17, 2015
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)Marc Bourlière, Jean-Pierre Bronowicki, Victor de Ledinghen, et al.Pageof 20